Literature DB >> 12171728

Immune reconstitution following hematopoietic stem-cell transplantation.

N Novitzky1, G M Davison.   

Abstract

BACKGROUND: Reconstitution of the immune system following allogeneic stem-cell transplantation is a complex process that requires successful engraftment of the hematopoietic stem cell, as well as adequate thymic function. As the majority of patients have reduced thymic function due to age, hormonal changes, as well as the damage caused by conditioning and GvHD, immune recovery is often delayed and incomplete. Following graft infusion there is rapid proliferation of natural killer (NK) cells that appear to proceed directly from the hematopoietic stem cell. B-cell function is dependent on specific maturation development in the BM micro-environment, as well as CD4 help. The CD8 population expands rapidly due to proliferation of many memory cells that react against Class I Ags, as well as viral molecules. Expansion of T-helper cells originates mainly from the memory pool that is present in the bone marrow graft. Naive cells require competent thymus hence the CD4 cell counts may be subnormal with clinical immunodeficiency. Controversy remains as to the capacity of the thymus to recover and thus extra thymic proliferation of T cells have been postulated. However these cells appear to have a limited capacity to expand and a fixed repertoire. DISCUSSION: Donor lymphocyte infusions may contribute a competent CD4 population that can cause GvHD, but have limitations in the capacity to respond to new antigens. Future research needs to be concentrated on improving the capacity of the thymus to reconstitute a functional naive population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12171728     DOI: 10.1080/146532401753174043

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

1.  Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1.

Authors:  Mari H Dallas; Barbara Varnum-Finney; Paul J Martin; Irwin D Bernstein
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

2.  A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.

Authors:  Sivasubramanian Baskar; Jessica M Suschak; Ivan Samija; Ramaprasad Srinivasan; Richard W Childs; Steven Z Pavletic; Michael R Bishop; Christoph Rader
Journal:  Blood       Date:  2009-08-10       Impact factor: 22.113

3.  Bone Marrow Stromal Cell Intraspinal Transplants Fail to Improve Motor Outcomes in a Severe Model of Spinal Cord Injury.

Authors:  John H Brock; Lori Graham; Eileen Staufenberg; Eileen Collyer; Jacob Koffler; Mark H Tuszynski
Journal:  J Neurotrauma       Date:  2015-11-13       Impact factor: 5.269

Review 4.  Alemtuzumab in stem cell transplantation.

Authors:  Geoff Hale
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

5.  Ex vivo expansion of CD34+ and T and NK cells from umbilical cord blood for leukemic BALB/C nude mouse transplantation.

Authors:  Yaming Wei; Yinfeng Huang; Yinze Zhang; Huayou Zhou; Qiong Cao; Qingbao Meng; Juncai Lan; Longhua Chen
Journal:  Int J Hematol       Date:  2008-02-08       Impact factor: 2.490

6.  Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation.

Authors:  Aurélie Tormo; Fatemeh Khodayarian; Yun Cui; Edouard Al-Chami; Reem Kanjarawi; Beatriz Noé; Huijie Wang; Moutih Rafei
Journal:  J Hematol Oncol       Date:  2017-06-14       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.